

GOLDEN AGRI-RESOURCES LTD
Full Year Financial Statement And Dividend Announcement
FINANCIAL HIGHLIGHTS

	Full Year 2021 US\$'000	Full Year 2020 US\$'000	Change %	2nd Half 2021 US\$'000	2nd Half 2020 US\$'000	Change %
Revenue	10,182,536	7,077,888	43.9	5,728,207	3,687,319	55.3
Gross Profit	2,354,610	1,150,042	104.7	1,293,733	761,504	69.9
EBITDA ¹	1,214,017	669,007	81.5	691,299	479,782	44.1
Underlying profit ²	602,862	230,187	161.9	356,899	241,564	47.7
Net profit attributable to owners of the Company	476,179	31,755	n.m.	322,965	188,625	71.2
Earnings per share (USD cents)	3.75	0.25	n.m.	2.54	1.49	71.2
Proposed final dividend per share (SGD cents)	1.077	0.48	124.4			
Total dividend per share (SGD cents)	1.605	0.48	234.4			

Notes:

- (1) Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain/(loss) from changes in fair value of biological assets, foreign exchange gain/(loss) and exceptional items.
- (2) Net profit attributable to owners of the Company excluding net effect of net gain or loss from changes in fair value of biological assets and depreciation of bearer plants, exceptional items and other non-operating items (foreign exchange gain or loss, net tax impact from tax-based asset revaluations, and other deferred tax income or expense).
- (3) n.m. – not meaningful.

A Condensed interim consolidated income statement and consolidated statement of comprehensive income

UNAUDITED CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

		Full Year 2021	Full Year 2020	Change	2nd Half 2021	2nd Half 2020	Change
	Note	US\$'000	US\$'000	%	US\$'000	US\$'000	%
Revenue	E4	10,182,536	7,077,888	43.9	5,728,207	3,687,319	55.3
Cost of sales		<u>(7,827,926)</u>	<u>(5,927,846)</u>	32.1	<u>(4,434,474)</u>	<u>(2,925,815)</u>	51.6
Gross Profit		<u>2,354,610</u>	<u>1,150,042</u>	104.7	<u>1,293,733</u>	<u>761,504</u>	69.9
Operating expenses							
Selling expenses		(1,272,233)	(548,864)	131.8	(651,236)	(309,933)	110.1
General and administrative expenses		<u>(353,790)</u>	<u>(295,266)</u>	19.8	<u>(206,619)</u>	<u>(157,356)</u>	31.3
Total operating expenses		<u>(1,626,023)</u>	<u>(844,130)</u>	92.6	<u>(857,855)</u>	<u>(467,289)</u>	83.6
Operating profit		<u>728,587</u>	<u>305,912</u>	138.2	<u>435,878</u>	<u>294,215</u>	48.1
Other income/(expenses)							
Financial income		23,015	15,787	45.8	11,842	8,459	40.0
Financial expenses		(164,833)	(141,384)	16.6	(82,315)	(71,107)	15.8
Share of results of associated companies, net of tax		4,003	4,203	(4.8)	1,995	3,177	(37.2)
Share of results of joint ventures, net of tax		34,432	619	n.m.	20,989	732	n.m.
Foreign exchange gain/(loss)		32,432	(32,099)	n.m.	41,203	16,154	155.1
Other operating income		<u>68,815</u>	<u>31,820</u>	116.3	<u>38,048</u>	<u>35,802</u>	6.3
		<u>(2,136)</u>	<u>(121,054)</u>	(98.2)	<u>31,762</u>	<u>(6,783)</u>	n.m.
Exceptional items							
Loss on disposal of a subsidiary		-	(265)	(100.0)	-	(265)	(100.0)
Allowance for impairment loss on property, plant and equipment		(941)	(530)	77.5	(941)	(530)	77.5
Impairment loss on investment in a joint venture		-	(5,372)	(100.0)	-	-	-
		<u>(941)</u>	<u>(6,167)</u>	(84.7)	<u>(941)</u>	<u>(795)</u>	18.4
Profit before tax	E5	725,510	178,691	306.0	466,699	286,637	62.8
Income tax	E6	<u>(198,929)</u>	<u>(116,580)</u>	70.6	<u>(113,801)</u>	<u>(78,065)</u>	45.8
Profit for the year/period		<u>526,581</u>	<u>62,111</u>	747.8	<u>352,898</u>	<u>208,572</u>	69.2
Attributable to:							
Owners of the Company		476,179	31,755	n.m.	322,965	188,625	71.2
Non-controlling interests		<u>50,402</u>	<u>30,356</u>	66.0	<u>29,933</u>	<u>19,947</u>	50.1
		<u>526,581</u>	<u>62,111</u>	747.8	<u>352,898</u>	<u>208,572</u>	69.2

Note:

(1) n.m. – not meaningful.

A Condensed interim consolidated income statement and consolidated statement of comprehensive income (cont'd)

**UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Full Year 2021 US\$'000	Full Year 2020 US\$'000	2nd Half 2021 US\$'000	2nd Half 2020 US\$'000
Profit for the year/period	<u>526,581</u>	<u>62,111</u>	<u>352,898</u>	<u>208,572</u>
Other comprehensive income/(loss):				
<u>Items that will not be reclassified subsequently to profit or loss:</u>				
Actuarial gain on post-employment benefits	5,755	6,848	5,252	8,755
Share of other comprehensive income/(loss) of:				
A joint venture	5	(21)	-	(21)
An associated company	9	11	(3)	9
Changes in fair value of financial assets at fair value through other comprehensive income	45,577	(100,579)	(28,942)	(52,265)
<u>Items that may be reclassified subsequently to profit or loss:</u>				
Foreign currency translation differences on consolidation	(2,655)	10,107	2,765	25,157
Share of other comprehensive income/(loss) of:				
Joint ventures	499	(860)	1,517	1,160
Associated companies	(138)	(1,105)	273	(1,001)
Other comprehensive income/(loss), net of tax	<u>49,052</u>	<u>(85,599)</u>	<u>(19,138)</u>	<u>(18,206)</u>
Total comprehensive income/(loss) for the year/period, net of tax	<u><u>575,633</u></u>	<u><u>(23,488)</u></u>	<u><u>333,760</u></u>	<u><u>190,366</u></u>
Total comprehensive income/(loss) attributable to:				
Owners of the Company	526,554	(53,396)	303,347	166,841
Non-controlling interests	49,079	29,908	30,413	23,525
	<u>575,633</u>	<u>(23,488)</u>	<u>333,760</u>	<u>190,366</u>

ADDITIONAL INFORMATION

Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain from changes in fair value of biological assets, foreign exchange gain/(loss) and exceptional items ("EBITDA")

	Full Year 2021 US\$'000	Full Year 2020 US\$'000	Change %	2nd Half 2021 US\$'000	2nd Half 2020 US\$'000	Change %
Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain from changes in fair value of biological assets and foreign exchange gain/(loss) and exceptional items ("EBITDA")	1,214,017	669,007	81.5	691,299	479,782	44.1
Interest on borrowings	(160,922)	(138,378)	16.3	(80,171)	(69,652)	15.1
Depreciation and amortisation	(364,934)	(329,441)	10.8	(188,005)	(162,503)	15.7
Net gain from changes in fair value of biological assets	5,858	15,769	(62.9)	3,314	23,651	(86.0)
Foreign exchange gain/(loss)	32,432	(32,099)	n.m.	41,203	16,154	155.1
Exceptional items	(941)	(6,167)	(84.7)	(941)	(795)	18.4
Profit before tax	<u>725,510</u>	<u>178,691</u>	306.0	<u>466,699</u>	<u>286,637</u>	62.8

Note:

(1) n.m. – not meaningful.

B Condensed interim statements of financial position

UNAUDITED STATEMENTS OF FINANCIAL POSITION

	Note	Group		Company	
		As at 31/12/2021 US\$'000	As at 31/12/2020 US\$'000	As at 31/12/2021 US\$'000	As at 31/12/2020 US\$'000
Assets					
Current Assets					
Cash and cash equivalents	E9	498,870	402,921	226	515
Short-term investments	E10	167,147	694,508	-	-
Trade receivables		782,942	737,203	-	-
Other current assets	E11	507,687	501,127	2,625	2,761
Biological assets		92,356	86,498	-	-
Inventories		1,383,155	935,459	-	-
		<u>3,432,157</u>	<u>3,357,716</u>	<u>2,851</u>	<u>3,276</u>
Non-Current Assets					
Long-term receivables and assets	E12	170,533	213,629	-	-
Long-term investments	E13	1,480,592	872,642	82,585	163,592
Subsidiary companies		-	-	3,429,024	3,429,024
Associated companies		25,592	23,359	-	-
Joint ventures		183,896	152,942	-	-
Investment properties		104	107	-	-
Property, plant and equipment		2,602,424	2,709,883	-	-
Bearer plants		1,396,471	1,416,734	-	-
Deferred tax assets		138,384	180,517	-	-
Intangible assets		177,958	198,851	-	-
		<u>6,175,954</u>	<u>5,768,664</u>	<u>3,511,609</u>	<u>3,592,616</u>
Total Assets		<u>9,608,111</u>	<u>9,126,380</u>	<u>3,514,460</u>	<u>3,595,892</u>

B Condensed interim statements of financial position (cont'd)

UNAUDITED STATEMENTS OF FINANCIAL POSITION (cont'd)

	Note	Group		Company	
		As at 31/12/2021 US\$'000	As at 31/12/2020 US\$'000	As at 31/12/2021 US\$'000	As at 31/12/2020 US\$'000
Liabilities and Equity					
Current Liabilities					
Short-term borrowings	E15	1,545,543	1,792,049	-	-
Bonds and notes payable	E15	90,999	153,859	-	-
Lease liabilities	E15	11,966	18,396	-	-
Trade payables		679,703	604,360	-	-
Other payables	E14	514,589	297,693	1,714	1,794
Taxes payable		91,993	22,820	-	-
		<u>2,934,793</u>	<u>2,889,177</u>	<u>1,714</u>	<u>1,794</u>
Non-Current Liabilities					
Bonds and notes payable	E15	357,800	113,195	-	-
Long-term borrowings	E15	974,286	1,042,740	-	-
Lease liabilities	E15	17,120	24,881	-	-
Deferred tax liabilities		166,824	154,676	-	-
Long-term payables and liabilities		265,284	470,097	352,468	231,813
		<u>1,781,314</u>	<u>1,805,589</u>	<u>352,468</u>	<u>231,813</u>
Total Liabilities		<u>4,716,107</u>	<u>4,694,766</u>	<u>354,182</u>	<u>233,607</u>
Equity Attributable to Owners of the Company					
Issued capital	E16	320,939	320,939	320,939	320,939
Share premium		1,216,095	1,216,095	1,850,965	1,850,965
Treasury shares	E16	(37,517)	(37,517)	(37,517)	(37,517)
Other paid-in capital		184,318	184,318	-	-
Other reserves					
Option reserve		31,471	31,471	31,471	31,471
Currency translation reserve		(11,476)	(10,411)	-	-
Fair value reserve		110,189	64,612	(197,930)	(91,453)
PRC statutory reserve		4,353	4,330	-	-
Other reserve		41,452	35,463	-	-
		175,989	125,465	(166,459)	(59,982)
Retained earnings		2,817,567	2,436,627	1,192,350	1,287,880
		<u>4,677,391</u>	<u>4,245,927</u>	<u>3,160,278</u>	<u>3,362,285</u>
Non-Controlling Interests		214,613	185,687	-	-
Total Equity		<u>4,892,004</u>	<u>4,431,614</u>	<u>3,160,278</u>	<u>3,362,285</u>
Total Liabilities and Equity		<u>9,608,111</u>	<u>9,126,380</u>	<u>3,514,460</u>	<u>3,595,892</u>

C Condensed interim statements of changes in equity

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2021

The Group	----- Attributable to Owners of the Company -----							Non-Controlling Interests	Total Equity
	Issued Capital	Share Premium	Treasury Shares	Other Paid-in Capital	Other Reserves	Retained Earnings	Total		
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000		
Balance at 1 Jan 2021	320,939	1,216,095	(37,517)	184,318	125,465	2,436,627	4,245,927	185,687	4,431,614
Profit for the year	-	-	-	-	-	476,179	476,179	50,402	526,581
Other comprehensive income/(loss)	-	-	-	-	50,398	(23)	50,375	(1,323)	49,052
Total comprehensive income for the year	-	-	-	-	50,398	476,156	526,554	49,079	575,633
Dividends paid (Note E17)	-	-	-	-	-	(95,216)	(95,216)	-	(95,216)
Dividends paid to non-controlling shareholders	-	-	-	-	-	-	-	(20,031)	(20,031)
Capital subscribed by non-controlling shareholders	-	-	-	-	126	-	126	(122)	4
Balance at 31 Dec 2021	320,939	1,216,095	(37,517)	184,318	175,989	2,817,567	4,677,391	214,613	4,892,004
Balance at 1 Jan 2020	320,939	1,216,095	(31,726)	184,318	210,142	2,457,300	4,357,068	148,376	4,505,444
Profit for the year	-	-	-	-	-	31,755	31,755	30,356	62,111
Other comprehensive loss	-	-	-	-	(84,641)	(510)	(85,151)	(448)	(85,599)
Total comprehensive (loss)/income for the year	-	-	-	-	(84,641)	31,245	(53,396)	29,908	(23,488)
Dividends paid (Note E17)	-	-	-	-	-	(51,918)	(51,918)	-	(51,918)
Shares buy back and held as treasury shares (Note E16)	-	-	(5,791)	-	-	-	(5,791)	-	(5,791)
Change in interest in a subsidiary	-	-	-	-	(36)	-	(36)	36	-
Disposal of a subsidiary	-	-	-	-	-	-	-	(11)	(11)
Waiver of loan from non-controlling shareholder	-	-	-	-	-	-	-	7,378	7,378
Balance at 31 Dec 2020	320,939	1,216,095	(37,517)	184,318	125,465	2,436,627	4,245,927	185,687	4,431,614

C Condensed interim statements of changes in equity (cont'd)

UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (cont'd) FOR THE YEAR ENDED 31 DECEMBER 2021

<u>The Company</u>	Issued Capital	Share Premium	Treasury Shares	Other Reserves	Retained Earnings	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
Balance at 1 Jan 2021	320,939	1,850,965	(37,517)	(59,982)	1,287,880	3,362,285
Loss for the year	-	-	-	-	(314)	(314)
Other comprehensive loss	-	-	-	(106,477)	-	(106,477)
Total comprehensive loss for the year	-	-	-	(106,477)	(314)	(106,791)
Dividends paid (Note E17)	-	-	-	-	(95,216)	(95,216)
Balance at 31 Dec 2021	<u>320,939</u>	<u>1,850,965</u>	<u>(37,517)</u>	<u>(166,459)</u>	<u>1,192,350</u>	<u>3,160,278</u>
Balance at 1 Jan 2020	320,939	1,850,965	(31,726)	9,326	1,336,846	3,486,350
Profit for the year	-	-	-	-	2,952	2,952
Other comprehensive loss	-	-	-	(69,308)	-	(69,308)
Total comprehensive (loss)/income for the year	-	-	-	(69,308)	2,952	(66,356)
Shares buy back and held as treasury shares (Note E16)	-	-	(5,791)	-	-	(5,791)
Dividends paid (Note E17)	-	-	-	-	(51,918)	(51,918)
Balance at 31 Dec 2020	<u>320,939</u>	<u>1,850,965</u>	<u>(37,517)</u>	<u>(59,982)</u>	<u>1,287,880</u>	<u>3,362,285</u>

D Condensed consolidated statements of cash flows

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2021

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>
Cash flows from operating activities		
Profit before tax	725,510	178,691
Adjustments for:		
Depreciation and amortisation	364,934	329,441
Net gain from changes in fair value of biological assets	(5,858)	(15,769)
Unrealised foreign exchange (gain)/loss	(3,581)	31,436
Share of results of associated companies, net of tax	(4,003)	(4,203)
Share of results of joint ventures, net of tax	(34,432)	(619)
(Gain)/Loss on disposal of property, plant and equipment	(1,416)	2,476
Bearer plants and property, plant and equipment written off	1,214	1,010
Non-trade receivables written off	1,510	4,206
Deferred charges written off	87	7
Allowance for impairment loss on:		
Inventories, net	12,153	1,047
Property, plant and equipment	941	530
Provision for expected credit loss on:		
Trade receivables, net	208	838
Non-trade receivables, net	373	102
Impairment loss on investment in a joint venture	-	5,372
Loss on disposal of a subsidiary	-	265
Changes in fair value of financial assets at fair value through profit or loss	(43,544)	7,139
Interest income	(23,015)	(15,787)
Interest expense	160,922	138,378
Operating cash flow before working capital changes	1,152,003	664,560
Changes in operating assets and liabilities:		
Trade receivables	(45,945)	(225,901)
Other current assets	(1,598)	63,586
Inventories	(459,888)	85,535
Trade payables	75,343	42,830
Other payables	16,082	187,333
Cash generated from operations	735,997	817,943
Interest paid	(147,565)	(129,928)
Interest received	16,390	12,817
Tax (paid)/refund	(40,027)	43,028
Net cash generated from operating activities	564,795	743,860

D Condensed consolidated statements of cash flows (cont'd)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS (cont'd) FOR THE YEAR ENDED 31 DECEMBER 2021

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>
Cash flows from investing activities		
Proceeds from disposal of property, plant and equipment	4,515	14,601
Proceeds from disposal of bearer plants	1,600	245
Capital expenditure on property, plant and equipment	(119,584)	(134,442)
Capital expenditure on bearer plants	(84,275)	(51,216)
Proceeds from redemption of/(Payments for) investment in financial assets, net	8,543	(123,959)
Investments in Plasma/KKPA Program plantations, net	(2,486)	(7,253)
Net cash inflow from acquisition of subsidiaries	-	8,980
Net cash inflow from disposal of a subsidiary	-	543
Dividend received from joint ventures	4,000	5,069
Dividend received from an associated company	1,224	1,190
Payments for deferred expenditure and intangible assets	(3,258)	(15,094)
Net increase in long-term receivables and assets	(6,472)	(19,276)
Net cash used in investing activities	<u>(196,193)</u>	<u>(320,612)</u>
Cash flows from financing activities		
Proceeds from short-term borrowings	4,581,069	4,449,407
Proceeds from long-term borrowings	309,394	109,217
Proceeds from bond issue	339,359	142,718
Payments of dividends	(115,247)	(51,918)
Payments of short-term borrowings	(4,925,399)	(4,540,912)
Payments of long-term borrowings	(284,227)	(305,361)
Payments of principal element of leases	(18,431)	(21,115)
Payments of bonds and notes payable	(152,627)	-
Payments for shares buy back	-	(5,791)
Capital subscribed by non-controlling shareholders	4	-
Payments of deferred loan charges and bank loan administration costs	(6,548)	(6,186)
Increase in cash in banks and time deposits pledged	(10,009)	(1,259)
Net cash used in financing activities	<u>(282,662)</u>	<u>(231,200)</u>
Net increase in cash and cash equivalents	85,940	192,048
Cash and cash equivalents at the beginning of the year	<u>399,173</u>	<u>207,125</u>
Cash and cash equivalents at the end of the year (Note E9)	<u>485,113</u>	<u>399,173</u>

E Notes to the condensed interim consolidated financial statements

1 Corporate information

Golden Agri-Resources Ltd (the “Company” or “GAR”) is a public limited company incorporated in Mauritius. The registered office is c/o IQ EQ Corporate Services (Mauritius) Ltd, 33 Edith Cavell Street, Port Louis, 11324, Mauritius.

The Company is principally engaged as an investment holding company. The principal activities of the subsidiaries, associated companies and joint ventures are described in Note 46 to the consolidated financial statements for the financial statements for the year ended 31 December 2020. These condensed interim consolidated financial statements as at and for year ended 31 December 2021 comprise the condensed financial statements of the Company and its subsidiaries (the “Group”).

2 Basis of preparation

The condensed interim consolidated financial statements of the Group for year ended 31 December 2021, have been prepared in accordance with International Accounting Standard (“IAS”) 34, *Interim Financial Reporting*.

The condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements for the year ended 31 December 2020.

The condensed interim consolidated financial statements are presented in United States dollar, which is the Company’s functional currency and presentation currency. All financial information presented in United States dollars have been rounded to the nearest thousand, unless otherwise stated.

2.1 New and revised International Financial Reporting Standards (“IFRSs”)

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with the IFRSs, except for the adoption of new and revised IFRSs effective for annual periods beginning on 1 January 2021. The adoption of the new and revised IFRSs has had no material financial impact on the condensed interim financial statements of the Group. The Group has not early adopted any other new and revised IFRSs that have been issued but are not yet effective.

2.2 Use of judgement and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Although these estimates are based on management’s best knowledge of current events and actions, actual results may actually differ from these estimates. The significant judgements made in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2020.

Estimates and underlying assumptions are reviewed on an ongoing basis. Financial impact arising from revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

3 Seasonal operations

The production of fresh fruit bunch (“FFB”) in oil palm plantations is subject to seasonal fluctuations as a result of weather conditions and rainfall patterns.

E Notes to the condensed interim consolidated financial statements (cont'd)

4 Segment and revenue information

	Full Year 2021	Full Year 2020	2nd Half 2021	2nd Half 2020
	<u>US\$'000</u>	<u>US\$'000</u>	<u>US\$'000</u>	<u>US\$'000</u>
Sales in Indonesia				
Third parties	1,609,871	1,298,384	905,625	667,558
Associated companies	15,829	7,494	7,574	4,257
Joint ventures	245,452	118,319	129,619	68,214
Related parties	9,971	6,479	6,234	3,246
	<u>1,881,123</u>	<u>1,430,676</u>	<u>1,049,052</u>	<u>743,275</u>
Sales outside Indonesia				
Third parties	8,301,198	5,647,080	4,679,037	2,943,969
Related parties	215	132	118	75
	<u>8,301,413</u>	<u>5,647,212</u>	<u>4,679,155</u>	<u>2,944,044</u>
	<u>10,182,536</u>	<u>7,077,888</u>	<u>5,728,207</u>	<u>3,687,319</u>

	Plantations and palm oil mills	Palm, laurics and others	Eliminations	Total
	<u>US\$'000</u>	<u>US\$'000</u>	<u>US\$'000</u>	<u>US\$'000</u>
<u>Full Year 2021</u>				
Revenue from external customers	32,891	10,149,645	-	10,182,536
Inter-segment sales	2,157,195	-	(2,157,195)	-
Total revenue	<u>2,190,086</u>	<u>10,149,645</u>	<u>(2,157,195)</u>	<u>10,182,536</u>
EBITDA	<u>779,215</u>	<u>434,354</u>	<u>448</u>	<u>1,214,017</u>
<u>Other information</u>				
Capital expenditure	156,399	45,221	-	201,620
Unallocated capital expenditure				2,239
Total capital expenditure				<u>203,859</u>
Depreciation and amortisation	(265,011)	(100,295)	372	(364,934)
Allowance for impairment loss on property, plant and equipment	-	(941)	-	(941)
Net gain from changes in fair value of biological assets	5,858	-	-	5,858
Gain from changes in fair value of financial assets at fair value through profit or loss	7,741	35,803	-	43,544
Interest on borrowings	(106,805)	(54,179)	62	(160,922)
Share of profit/(loss) of:				
Associated companies	(342)	4,345	-	4,003
Joint ventures	-	34,432	-	34,432
<u>Assets</u>				
Segment assets	5,320,555	4,345,023	(1,874,173)	7,791,405
Investment in:				
Associated companies	2,548	23,044	-	25,592
Joint ventures	-	183,896	-	183,896
Unallocated assets				1,607,218
Total assets				<u>9,608,111</u>
<u>Liabilities</u>				
Segment liabilities	(633,619)	(3,359,507)	1,859,228	(2,133,898)
Unallocated liabilities				(2,582,209)
Total liabilities				<u>(4,716,107)</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

4 Segment and revenue information (cont'd)

<u>Full Year 2020</u>	<u>Plantations and palm oil mills</u> US\$'000	<u>Palm, laurics and others</u> US\$'000	<u>Eliminations</u> US\$'000	<u>Total</u> US\$'000
Revenue from external customers	19,590	7,058,298	-	7,077,888
Inter-segment sales	1,462,567	-	(1,462,567)	-
Total revenue	<u>1,482,157</u>	<u>7,058,298</u>	<u>(1,462,567)</u>	<u>7,077,888</u>
 EBITDA	 <u>416,098</u>	 <u>255,010</u>	 <u>(2,101)</u>	 <u>669,007</u>
 <u>Other information</u>				
Capital expenditure	118,414	67,224	-	185,638
Unallocated capital expenditure				20
Total capital expenditure				<u>185,658</u>
 Depreciation and amortisation	 (227,606)	 (102,378)	 543	 (329,441)
Allowance for impairment loss on property, plant and equipment	-	(530)	-	(530)
Impairment loss on investment in a joint venture	-	(5,372)	-	(5,372)
Net gain from changes in fair value of biological assets	15,769	-	-	15,769
Loss from changes in fair value of financial assets at fair value through profit or loss	(3,271)	(3,868)	-	(7,139)
Interest on borrowings	(91,206)	(47,172)	-	(138,378)
Share of profit of:				
Associated companies	587	3,616	-	4,203
Joint ventures	-	619	-	619
 <u>Assets</u>				
Segment assets	5,012,637	3,747,936	(1,438,478)	7,322,095
Investment in:				
Associated companies	2,921	20,438	-	23,359
Joint ventures	-	152,942	-	152,942
Unallocated assets				1,627,984
Total assets				<u>9,126,380</u>
 <u>Liabilities</u>				
Segment liabilities	(623,355)	(2,933,947)	1,432,219	(2,125,083)
Unallocated liabilities				(2,569,683)
Total liabilities				<u>(4,694,766)</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

4 Segment and revenue information (cont'd)

<u>2nd Half 2021</u>	<u>Plantations and palm oil mills</u> <u>US\$'000</u>	<u>Palm, laurics and others</u> <u>US\$'000</u>	<u>Eliminations</u> <u>US\$'000</u>	<u>Total</u> <u>US\$'000</u>
Revenue from external customers	11,810	5,716,397	-	5,728,207
Inter-segment sales	1,135,165	-	(1,135,165)	-
Total revenue	<u>1,146,975</u>	<u>5,716,397</u>	<u>(1,135,165)</u>	<u>5,728,207</u>
EBITDA	<u>414,174</u>	<u>275,948</u>	<u>1,177</u>	<u>691,299</u>
<u>Other information</u>				
Capital expenditure	108,068	29,014	-	137,082
Unallocated capital expenditure				1,213
Total capital expenditure				<u>138,295</u>
Depreciation and amortisation	(138,427)	(49,722)	144	(188,005)
Allowance for impairment loss on property, plant and equipment	-	(941)	-	(941)
Net gain from changes in fair value of biological assets	3,314	-	-	3,314
Gain from changes in fair value of financial assets at fair value through profit or loss	2,567	29,636	-	32,203
Interest on borrowings	(51,500)	(28,733)	62	(80,171)
Share of profit/(loss) of:				
Associated companies	(102)	2,097	-	1,995
Joint ventures	-	20,989	-	20,989
				<u>20,989</u>
<u>2nd Half 2020</u>	<u>Plantations and palm oil mills</u> <u>US\$'000</u>	<u>Palm, laurics and others</u> <u>US\$'000</u>	<u>Eliminations</u> <u>US\$'000</u>	<u>Total</u> <u>US\$'000</u>
Revenue from external customers	11,480	3,675,839	-	3,687,319
Inter-segment sales	845,750	-	(845,750)	-
Total revenue	<u>857,230</u>	<u>3,675,839</u>	<u>(845,750)</u>	<u>3,687,319</u>
EBITDA	<u>284,389</u>	<u>196,840</u>	<u>(1,447)</u>	<u>479,782</u>
<u>Other information</u>				
Capital expenditure	65,665	38,441	-	104,106
Unallocated capital expenditure				(144)
Total capital expenditure				<u>103,962</u>
Depreciation and amortisation	(112,462)	(50,540)	499	(162,503)
Allowance for impairment loss on property, plant and equipment	-	(530)	-	(530)
Net gain from changes in fair value of biological assets	23,651	-	-	23,651
Changes in fair value of financial assets at fair value through profit or loss	(582)	7,302	-	6,720
Interest on borrowings	(49,084)	(20,568)	-	(69,652)
Share of profit of:				
Associated companies	822	2,355	-	3,177
Joint ventures	-	732	-	732
				<u>732</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

4 Segment and revenue information (cont'd)

The following is an analysis of revenue and based on geographical location of customers is as follows:

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>	2nd Half 2021 <u>US\$'000</u>	2nd Half 2020 <u>US\$'000</u>
China	1,175,182	801,991	696,181	469,657
Indonesia	1,881,123	1,430,676	1,049,052	743,275
India	1,980,008	1,296,826	1,106,776	645,794
Rest of Asia	2,627,781	1,835,304	1,473,132	939,008
Europe	1,512,517	1,098,671	819,450	562,816
Others	1,005,925	614,420	583,616	326,769
Consolidated revenue	<u>10,182,536</u>	<u>7,077,888</u>	<u>5,728,207</u>	<u>3,687,319</u>

The following is an analysis of the carrying amount of non-current non-financial assets, analysed by the geographical areas in which the assets are located:

	31.12.2021 <u>US\$'000</u>	31.12.2020 <u>US\$'000</u>
Indonesia	4,080,267	4,209,433
China	95,860	101,408
Singapore	133,931	136,859
India	75,994	74,753
Others	42,950	45,475
Total non-current non-financial assets	<u>4,429,002</u>	<u>4,567,928</u>

5 Profit before tax

The following items have been credited/(charged) against profit before tax

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>	2nd Half 2021 <u>US\$'000</u>	2nd Half 2020 <u>US\$'000</u>
Depreciation expenses	(341,398)	(325,519)	(168,145)	(160,614)
Gain/(Loss) on disposal of property, plant and equipment	1,416	(2,476)	2,224	(2,677)
Bearer plants and property, plant and equipment written off	(1,214)	(1,010)	(451)	(529)
(Allowance for)/Write-back of impairment loss on inventories	(12,153)	(1,047)	10,379	3,116
Impairment loss on investment in a joint venture	-	(5,372)	-	-
Gain/(Loss) from changes in fair value of financial assets at FVTPL	<u>43,544</u>	<u>(7,139)</u>	<u>32,203</u>	<u>6,720</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

5 Profit before tax (cont'd)

Related party transactions

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>	2nd Half 2021 <u>US\$'000</u>	2nd Half 2020 <u>US\$'000</u>
(i) Sale of services				
Rental income from related parties	376	368	228	218
Rental income from joint ventures	105	215	48	109
Rental income from an associated company	20	1	20	1
(ii) Purchase of goods and services				
Insurance premium to a related party	6,086	5,798	3,199	4,117
Purchase of non-palm oil products and services from related parties	85,992	50,148	54,794	20,061
Freight and related expenses to joint ventures	5,787	2,371	3,589	1,317
Rental and service charge expense to related parties	211	136	66	116
Rental and service charge expense to an associated company	31	97	31	97
(iii) Dividend income from:				
- joint ventures	4,000	5,069	4,000	1,500
- an associated company	<u>1,224</u>	<u>1,190</u>	<u>1,224</u>	<u>1,190</u>

6 Income tax

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>	2nd Half 2021 <u>US\$'000</u>	2nd Half 2020 <u>US\$'000</u>
Current income tax	147,187	47,897	90,001	38,182
Deferred income tax	<u>51,742</u>	<u>68,683</u>	<u>23,800</u>	<u>39,883</u>
	<u>198,929</u>	<u>116,580</u>	<u>113,801</u>	<u>78,065</u>

7 Earnings per share

	Full Year 2021	Full Year 2020	2nd Half 2021	2nd Half 2020
Earnings per ordinary share for the period:				
(i) Based on weighted average number of ordinary shares	USD3.75cents	USD0.25cents	USD2.54cents	USD1.49cents
- Weighted average number of shares	12,692,073,056	12,699,848,082	12,692,073,056	12,692,073,056
(ii) On a fully diluted basis	Not applicable	Not applicable	Not applicable	Not applicable
- Weighted average number of shares	Not applicable	Not applicable	Not applicable	Not applicable

E Notes to the condensed interim consolidated financial statements (cont'd)

8 Net asset value per share

	The Group		The Company	
	As at 31 Dec 2021	As at 31 Dec 2020	As at 31 Dec 2021	As at 31 Dec 2020
Net asset value (total assets less total liabilities) per ordinary share based on existing issued share capital of 12,692,073,056 shares	US\$0.39	US\$0.35	US\$0.25	US\$0.26

9 Cash and cash equivalents

	<u>Group</u>	
	31.12.2021	31.12.2020
	<u>US\$'000</u>	<u>US\$'000</u>
Time deposits, cash and bank balances	498,870	402,921
Less: Cash in banks and time deposits pledged	(13,757)	(3,748)
Cash and cash equivalents in the consolidated statement of cash flows	<u>485,113</u>	<u>399,173</u>

10 Short-term investments

	<u>Group</u>	
	31.12.2021	31.12.2020
	<u>US\$'000</u>	<u>US\$'000</u>
Time deposits	<u>133,548</u>	<u>74,558</u>
Equity securities at FVOCI	<u>15,745</u>	<u>18,950</u>
Financial assets at FVTPL:		
Equity securities held for trading	8,167	10,247
Debt securities held for trading	9,687	140,436
Convertible debt securities held for trading	-	450,317
	<u>17,854</u>	<u>601,000</u>
	<u>167,147</u>	<u>694,508</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

11 Other current assets

	Group		Company	
	31.12.2021 US\$'000	31.12.2020 US\$'000	31.12.2021 US\$'000	31.12.2020 US\$'000
Prepaid expenses	17,162	24,581	28	26
Prepaid taxes	106,928	107,578	-	-
Deposits and advances to suppliers	199,356	117,834	-	-
Derivative receivable	33,385	98,058	-	-
Others	137,425	141,347	1	1
	494,256	489,398	29	27
Receivable from joint ventures	13,315	11,568	-	-
Receivable from related parties	116	161	-	-
Receivable from subsidiaries	-	-	2,596	2,734
	507,687	501,127	2,625	2,761

12 Long-term receivables and assets

	Group		Company	
	31.12.2021 US\$'000	31.12.2020 US\$'000	31.12.2021 US\$'000	31.12.2020 US\$'000
Loans receivable from joint ventures and an associated company	51,821	32,763	-	-
Tax recoverable	76,155	114,814	-	-
Advances for plasma plantations, net	13,785	11,464	-	-
Advances for projects	5,077	30,162	-	-
Land clearing	4,701	4,190	-	-
Advances for investment in land	1,495	1,495	-	-
Others	17,499	18,741	-	-
	170,533	213,629	-	-

13 Long-term investments

	Group		Company	
	31.12.2021 US\$'000	31.12.2020 US\$'000	31.12.2021 US\$'000	31.12.2020 US\$'000
Equity securities at FVOCI	882,641	747,594	82,585	163,592
Financial assets at FVTPL:				
Equity/Fund securities	139,019	125,048	-	-
Convertible debt securities	458,932	-	-	-
	1,480,592	872,642	82,585	163,592

14 Other payables

	Group		Company	
	31.12.2021 US\$'000	31.12.2020 US\$'000	31.12.2021 US\$'000	31.12.2020 US\$'000
Advances and deposits	151,032	81,987	-	-
Accrued expenses	120,807	81,907	311	368
Payable to third parties	187,225	77,691	-	-
Others	51,247	51,781	8	8
	510,311	293,366	319	376
Payable to related parties	4,278	4,327	1,395	1,418
	514,589	297,693	1,714	1,794

E Notes to the condensed interim consolidated financial statements (cont'd)

15 Borrowings

	Group	
	31.12.2021 <u>US\$'000</u>	31.12.2020 <u>US\$'000</u>
Current liabilities		
Short-term borrowings	1,545,543	1,792,049
Bonds and notes payable	90,999	153,859
Lease liabilities	11,966	18,396
	<u>1,648,508</u>	<u>1,964,304</u>
Non-current liabilities		
Long-term borrowings	974,286	1,042,740
Bonds and notes payable	357,800	113,195
Lease liabilities	17,120	24,881
	<u>1,349,206</u>	<u>1,180,816</u>
	<u>2,997,714</u>	<u>3,145,120</u>

	31.12.2021 <u>US\$'000</u>			31.12.2020 <u>US\$'000</u>		
	Secured	Unsecured	Total	Secured	Unsecured	Total
Amount repayable in one year or less	1,030,117	618,391	1,648,508	1,238,773	725,531	1,964,304
Amount repayable after one year	891,457	457,749	1,349,206	861,941	318,875	1,180,816
Total	<u>1,921,574</u>	<u>1,076,140</u>	<u>2,997,714</u>	<u>2,100,714</u>	<u>1,044,406</u>	<u>3,145,120</u>

The secured borrowings are collateralised by certain cash and cash equivalents, short-term investments, inventories, trade receivables, bearer plants, biological assets and property, plant and equipment.

16 Issued capital and treasury shares

	<u>No. of ordinary shares</u>		<u>Amount</u>	
	<u>Issued capital</u>	<u>Treasury shares</u>	<u>Issued capital</u> <u>US\$'000</u>	<u>Treasury shares</u> <u>US\$'000</u>
Issued and fully paid:				
Balance at 1 January 2020	12,837,548,556	(102,792,400)	320,939	(31,726)
Treasury shares purchased	-	(42,683,100)	-	(5,791)
Balance at 31 December 2020	<u>12,837,548,556</u>	<u>(145,475,500)</u>	<u>320,939</u>	<u>(37,517)</u>
Balance at 1 January 2021 and 31 December 2021	<u>12,837,548,556</u>	<u>(145,475,500)</u>	<u>320,939</u>	<u>(37,517)</u>

There were no movements in the Company's issued capital since 31 December 2020.

E Notes to the condensed interim consolidated financial statements (cont'd)

17 Dividends paid

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>
Interim dividend paid in respect of current year of US\$0.00528 (FY2020: S\$ Nil) per share	49,523	-
Final dividend paid in respect of previous year of S\$0.0048 (FY2020: S\$0.0058) per share	<u>45,693</u>	<u>51,918</u>
	<u>95,216</u>	<u>51,918</u>

At the Annual Meeting to be held on 29 April 2022, a final dividend (tax not applicable) of S\$0.01077 per share, amounting to S\$136,693,626.81 (equivalent to approximately US\$101,180,000) will be recommended. These financial statements do not reflect this dividend, which will be accounted for in shareholders' equity as an appropriation of retained earnings for the financial year ending 31 December 2022.

18 Financial instruments

Fair Value of Financial Instruments

The carrying amounts of financial assets and liabilities with a maturity of less than one year, which include cash and cash equivalents, time deposits, short-term investments, trade and other receivables, trade and other payables and short-term interest-bearing borrowings are assumed to approximate their fair values due to their short-term maturities.

The fair values of long-term receivables and long-term interest-bearing borrowings are calculated based on discounted expected future principal and interest cash flows. The discount rates used are based on market rates for similar instruments at the end of the reporting period. As at 31 December 2021 and 2020, the carrying amounts of the long-term receivables and long-term interest-bearing borrowings approximate their fair values.

Fair Value Hierarchy

The following table presents financial assets and financial liabilities measured at fair value on a recurring basis and classified by level of the following fair value measurement hierarchy:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is as prices) or indirectly (i.e. derived from prices); and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	<u>Level 1</u> <u>US\$'000</u>	<u>Level 2</u> <u>US\$'000</u>	<u>Level 3</u> <u>US\$'000</u>	<u>Total</u> <u>US\$'000</u>
<u>At 31 December 2021</u>				
Financial assets at FVOCI (Equity)	-	-	898,386	898,386
Financial assets at FVTPL held for trading	3,641	8,756	603,408	615,805
Derivative receivable	-	33,385	-	33,385
Derivative payable	-	(109,985)	-	(109,985)
	<u>3,641</u>	<u>(67,844)</u>	<u>1,501,794</u>	<u>1,437,591</u>
<u>At 31 December 2020</u>				
Financial assets at FVOCI (Equity)	-	-	766,544	766,544
Financial assets at FVTPL held for trading	5,684	10,591	709,773	726,048
Derivative receivable	-	98,058	-	98,058
Derivative payable	-	(26,763)	-	(26,763)
	<u>5,684</u>	<u>81,886</u>	<u>1,476,317</u>	<u>1,563,887</u>

E Notes to the condensed interim consolidated financial statements (cont'd)

18 Financial instruments (cont'd)

Methods and Assumptions Used to Determine Fair Values

The methods and assumptions used by management to determine fair values are as follows:

(i) Level 1 fair value measurements

The fair value of securities traded in active markets is based on quoted market prices at the reporting date.

(ii) Level 2 fair value measurements

Fair value of forward currency contracts is calculated by reference to current forward exchange rates for contracts with similar maturity profiles as at the reporting date. The fair value of unquoted debt and equity securities is determined by reference to fund statements provided by non-related fund managers. For commodity futures contracts, observable prices are used as a measure of fair values for the outstanding contracts. For firm commitment contracts, the fair values are based on market prices and management's best estimate and are arrived at by reference to the market prices of another contract that is substantively similar and adjusted for premium or discount where relevant.

(iii) Level 3 fair value measurements

The fair values of financial assets classified under Level 3 of the fair value hierarchy were determined by reference to fund statements provided by non-related fund managers and valuation reports prepared by independent professional valuers. Valuation techniques included:

- Net present value method – Fair value was determined by reference to valuations performed using the net present value method on its underlying assets, adjusted for the external borrowings. Forecasts of future cash flows are based on historical results, growth rate using industry trends, discount rate based on capital fund structure, general market and economic conditions, taking into account any weighted estimation uncertainty on cash flows due to the impact of the Covid-19 pandemic.
- Fund statements – Fair value was made with reference to the fund statements provided by non-related fund managers. The fund managers determined the fair value of its entire portfolio using multiple valuation techniques including price of recent transactions, Backsolve and option pricing model, Monte Carlo simulation, adjusted net assets value and discounted cash flow method of the investee companies, taking into consideration any investee's underlying businesses that were affected by the impact of the Covid-19 pandemic.

19 Significant capital expenditure commitments

At the end of the reporting period, the estimated significant expenditure committed but not provided for in the consolidated financial statements amounted to US\$61,733,000 (31.12.2020: US\$31,895,000).

20 Subsequent events

As announced on 8 August 2021, the Group's subsidiary, Gemini Edibles & Fats India Limited ("GEF") has initiated the process for its proposed listing on the BSE Limited and the National Stock Exchange of India (the "Proposed Listing") and, in this connection, has filed a draft red herring prospectus dated 7 August 2021 with the Securities and Exchange Board of India ("SEBI"). Should GEF's application for the Proposed Listing be approved by SEBI, it is envisaged that there will be an initial public offering and the Group is anticipated to continue being the largest shareholder of GEF, post-Listing and for the foreseeable future. The Company will make further announcement(s) as and when there are material development(s) in relation to the Proposed Listing.

F Other information required by Listing Rule Appendix 7.2

1 Review

The condensed interim consolidated statement of financial position of Golden Agri-Resources Ltd (the “Company”) and its subsidiaries as at 31 December 2021 and the related condensed consolidated income statements and statement of other comprehensive income, condensed statement of changes in equity and condensed statement of cash flows for the year then ended and certain explanatory notes have not been audited or reviewed.

2 Review of performance of the Group

	Full Year 2021 <u>US\$'000</u>	Full Year 2020 <u>US\$'000</u>	Change %	2nd Half 2021 <u>US\$'000</u>	2nd Half 2020 <u>US\$'000</u>	Change %
Revenue by segment						
Plantations and palm oil mills	2,190,086	1,482,157	47.8	1,146,975	857,230	33.8
Palm, laurics and others	10,149,645	7,058,298	43.8	5,716,397	3,675,839	55.5
Inter-segment eliminations	<u>(2,157,195)</u>	<u>(1,462,567)</u>	47.5	<u>(1,135,165)</u>	<u>(845,750)</u>	34.2
Total Revenue	<u>10,182,536</u>	<u>7,077,888</u>	43.9	<u>5,728,207</u>	<u>3,687,319</u>	55.3
EBITDA by segment						
Plantations and palm oil mills	779,215	416,098	87.3	414,174	284,389	45.6
Palm, laurics and others	434,354	255,010	70.3	275,948	196,840	40.2
Inter-segment eliminations	<u>448</u>	<u>(2,101)</u>	n.m.	<u>1,177</u>	<u>(1,447)</u>	n.m.
Total EBITDA	<u>1,214,017</u>	<u>669,007</u>	81.5	<u>691,299</u>	<u>479,782</u>	44.1

Notes:

- (1) EBITDA refers to earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain/(loss) from changes in fair value of biological assets, foreign exchange gain/(loss) and exceptional items.
- (2) Plantations and palm oil mills segment refers to products from upstream business.
- (3) Palm, laurics and others segment refers to processing and merchandising of palm and oilseed based products i.e. bulk, branded, oleo-chemicals and other vegetable oils, as well as production and distribution of other consumer products in China and Indonesia mainly food and beverages.

REVIEW OF PERFORMANCE FOR THE YEAR ENDED 31 DECEMBER 2021

The Group recorded revenue of US\$10,182.5 million for year ended 31 December 2021 (“FY2021”) as compared to US\$7,077.9 million in the previous year (“FY2020”). This represented an increase of 43.9% as compared to FY2020 and was mainly due to the strong international crude palm oil (“CPO”) prices, higher production output and improved margins from our downstream business. Consequently, EBITDA increased by 81.5% to US\$1,214.0 million, while net profit for the year was higher at US\$526.6 million.

PLANTATIONS AND PALM OIL MILLS

Revenue from our plantations and palm oil mills segment increased by 47.8% to US\$2,190.1 million in FY2021, mainly driven by higher CPO prices and higher production during the current year. Consequently, EBITDA from our plantations and palm oil mills segment increased from US\$416.1 million in the previous year to US\$779.2 million in the current year. The average international CPO (FOB Belawan) price for the current year was 69.0% higher at US\$1,168 per tonne as compared to US\$691 per tonne in the previous year. However, after deducting the export tax and levy, the average CPO price was US\$819 per tonne, 31% higher than in the previous year.

Our fresh fruit bunch (“FFB”) and palm product output for the year were higher at 9,660,000 tonnes and 2,961,000 tonnes respectively as compared to 9,297,000 tonnes and 2,775,000 tonnes respectively in FY2020.

PALM, LAURICS AND OTHERS

Our palm, laurics and others segment refers to all processing and merchandising of palm and oilseeds product, oleochemicals and other vegetable oils, as well as production and distribution of other consumer products in China and Indonesia.

Our palm, laurics and others segment reported increased revenue at US\$10,149.6 million with EBITDA increased by 70.3% to US\$434.4 million in the current year largely attributable to higher average selling prices. Positive market developments in the second half of 2021 resulted in higher sales volume as compared to the first half of 2021, bringing the full year sales volume to the same level as the previous year. Despite the similar sales volume, our strategy towards more value-added products has resulted in the increase in EBITDA margin from 3.6% in FY2020 to 4.3% and translated into higher EBITDA of US\$434.4 million for the current year.

F Other information required by Listing Rule Appendix 7.2 (cont'd)

FINANCIAL EXPENSES, NET

Net financial expenses comprised net interest expenses (after deducting interest income), amortisation of deferred loan charges and other finance charges. Net financial expenses increased from US\$125.6 million in the previous year to US\$141.8 million in the current year mainly due to higher cost of fund during the current period in line with higher IDR denominated borrowings. The Group manage the increased cost of fund through hedging instruments, where changes in fair value of foreign currency hedging instruments were reported as part of the foreign exchange gain (loss).

SHARE OF RESULTS OF JOINT VENTURES, NET

The Group recorded share of profit in joint ventures of US\$34.4 million in the current year as compared US\$0.6 million in the previous year. This was mainly attributable to the improved operating performance in a joint venture during the current year.

FOREIGN EXCHANGE GAIN/(LOSS), NET

The Group recorded a net foreign exchange gain of US\$32.4 million in FY2021 as compared to net foreign exchange loss of US\$32.1 million in FY2020. The current year's gain was mainly attributable to translation foreign exchange gain arising from Indonesian Rupiah ("IDR") denominated monetary balances and fair value gain on forward foreign currency contracts entered to hedge the currency exposure. The previous year's loss was mainly attributable to unrealised translation loss arising from IDR denominated monetary balances.

OTHER OPERATING INCOME, NET

Net other operating income comprised mainly changes in fair value of biological assets (agricultural produce) and financial assets, income from sales of seedlings and other materials, as well as rental income. The net operating income increased from US\$31.8 million in FY2020 to US\$68.8 million mostly due to fair value gain from changes in fair value of financial assets recorded in the current year as compared to fair value loss recorded in the previous year, partially offset by lower fair value gain on biological assets.

EXCEPTIONAL ITEMS, NET

The current year's exceptional loss related to impairment loss made on certain fixed assets in China.

INCOME TAX

Income tax comprised provision for current and deferred income tax derived by applying the varying statutory tax rates of the different countries in which the Group operates on its taxable profit and taxable temporary difference. No group relief is available for set-off of taxable profits against tax losses of companies within the Group. Net tax expense was higher at US\$198.9 million in FY2021 mainly in line with higher taxable profit recorded in certain subsidiaries during the current year.

REVIEW OF FINANCIAL POSITION AS AT 31 DECEMBER 2021

ASSETS

The Group's total assets were higher at US\$9,608.1 million as at end of 2021 as compared to US\$9,126.4 million as at end 2020.

Inventory increased from US\$935.5 million as at end 2020 to US\$1,383.2 million mainly due to higher inventory amount for our downstream businesses, in line with higher commodity prices.

Total short-term investments and long-term investments increased by US\$80.6 million to mainly due to fair value gain recorded during the current year. Short-term investments decreased by US\$527.4 million to US\$167.1 million mainly due to reclassification of certain investment from short-term investments to long-term investments.

F Other information required by Listing Rule Appendix 7.2 (cont'd)

LIABILITIES

Total liabilities of the Group increased marginally from US\$4,694.8 million as at end 2020 to US\$4,716.1 million as at end 2021.

Other current payables increased by US\$216.9 million mainly due to increases in accrued operating expense, advances received from customers and other payables.

Long-term payables and liabilities decreased from US\$470.1 million to US\$265.3 million mainly due to settlements made during the current year.

Total borrowings decreased by US\$147.4 million following repayments made during the current year.

REVIEW OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2021

Operating cash flow before working capital changes improved significantly from US\$664.6 million in the previous year to US\$1,152.0 million following the better operating performance for the current year.

This higher operating cash flow was used to fund the increased working capital requirements of US\$416.0 million that resulted from the higher carrying value of inventories. Coupled with the tax payment during the year, our net cash generated from operating activities was lower at US\$564.8 million as compared to US\$743.9 million in previous year.

Net cash used in investing activities of US\$196.2 million was mainly related to capital expenditures on our plantations, and property, plant and equipment during the current year.

Net cash used in financing activities of US\$282.7 million was mainly related to net repayment for borrowings and payments for dividends during the current year.

Cash and cash equivalents (net of deposits pledged) of the Group has increased from US\$399.2 million as at end of last year to US\$485.1 million.

3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable.

4 A commentary at the date of the announcement of the competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

The Group's operating performance will continue to be affected by speed of recovery of economic activities to the pre-pandemic levels, the prices of CPO and competing seed oils, developments in government policy on import duties and export taxes of the countries we trade and weather conditions. Overall the outlook of CPO prices remains favorable due to the tightness in global vegetable oil supply, while demand for CPO is estimated to remain firm due to staple usage for food, oleochemicals and energy sector. The Group will continue to monitor these situations closely, especially the health and safety of our employees. The Group will also continue to implement comprehensive measures to minimise the impact on our business operations and to optimise profit opportunities.

We expect the CPO prices to remain firm supported by global demand growth, including the continuous implementation of the biodiesel mandate in Indonesia. The Group will continue to enhance its integrated operation capabilities to optimise profit opportunities across the value chain, as well as to improve its yield, cost efficiency and sustainability initiatives.

F Other information required by Listing Rule Appendix 7.2 (cont'd)

5 Dividend

(a) Current Financial Period Reported On

Any ordinary dividend declared for the current financial period reported on? Yes.

Name of Dividend:	Proposed final dividend
Dividend Type:	Cash
Dividend Amount per share:	1.077 Singapore cents per ordinary share
Number of shares:	12,692,073,056
Tax Rate:	Tax not applicable

Name of Dividend:	Interim dividend
Dividend Type:	Cash
Dividend Amount per share:	0.528 Singapore cents per ordinary share
Number of shares:	12,692,073,056
Tax Rate:	Tax not applicable

(b) Corresponding Period of the Immediately Preceding Financial Year

Any ordinary dividend declared for the corresponding period of the immediately preceding financial year? Yes.

Name of Dividend:	Proposed final dividend
Dividend Type:	Cash
Dividend Amount per share:	0.48 Singapore cents per ordinary share
Number of shares:	12,692,073,056
Tax Rate:	Tax not applicable

(c) Date payable

Subject to ordinary shareholders' approval at the Annual Meeting to be held on 29 April 2022, the proposed final ordinary dividend for financial year ended 31 December 2021 will be payable on 17 May 2022.

(d) Record date

5.00 p.m. on 6 May 2022.

6 If no dividend has been declared/recommended, a statement to that effect

Not applicable.

F Other information required by Listing Rule Appendix 7.2 (cont'd)

7 Interested persons transactions disclosure

Name of interested person ("IP")	Nature of Relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate* pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate* pursuant to Rule 920 (excluding transactions less than S\$100,000)
		US\$	US\$
Ningbo Asia Paper Tube & Cartons Box Co., Ltd	#1	Nil	82,254 #2
Ningbo Asia Pulp & Paper Co., Ltd	#1	Nil	222,823
PT Asuransi Sinar Mas	#1	Nil	6,256,656
PT Bank Sinarmas Tbk ("BSM")	#1	Nil	44,543,089 #3
PT Cakrawala Mega Indah ("CMI")	#1	Nil	14,534,188 #4
PT Indah Kiat Pulp & Paper Tbk	#1	Nil	710,221
PT Kreasi Kotakmegah	#1	Nil	882,093
PT Pindo Deli Pulp and Paper Mills	#1	Nil	217,312
PT Rolimex Kimia Nusamas ("RKN")	#1	Nil	54,588,094 #5
PT Roundhill Capital Indonesia ("RCI")	#1	Nil	19,976,033 #6
PT Royal Oriental	#1	Nil	1,904,132
PT Sinar Mas Tjpta	#1	Nil	770,000
PT Sinarmas Sekuritas	#1	Nil	297,675
Sinarmas Land Limited	#1	Nil	109,844
Total		Nil	145,094,414

Notes:-

- * Renewed at GAR's Annual Meeting on 28 April 2021 pursuant to Rule 920 of the listing manual of the SGX-ST ("Listing Manual").
- #1 These IPs are regarded as associates of GAR's controlling shareholder under Chapter 9 of the Listing Manual on interested person transactions.
- #2 Amount exceeds S\$100,000.
- #3 Time deposits and current account placements with BSM during the year. Principal amount of placements as at 31 December 2021 is approximately USD5.81million.
- #4 Purchase of paper products and chemicals from CMI.
- #5 Purchase of fertilizers and chemicals from RKN; sale of oleochemical and by-products biodiesel to RKN.
- #6 Purchase of coal from RCI.

F Other information required by Listing Rule Appendix 7.2 (cont'd)

8 A breakdown of sales

	The Group		
	2021 US\$'000	2020 US\$'000	% Increase/ (Decrease)
(a) Sales reported for first half year	4,454,329	3,390,569	31.4
(b) Operating profit/(loss) after tax before deducting non-controlling interests reported for first half year	173,683	(146,461)	n.m.
(c) Sales reported for second half year	5,728,207	3,687,319	55.3
(d) Operating profit after tax before deducting non-controlling interests reported for second half year	352,898	208,572	69.2

9 A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year

	<u>2021 US\$'000</u>	<u>2020 US\$'000</u>
Ordinary - interim	49,523	-
Ordinary - proposed final	101,180	45,693
Ordinary - total	<u>150,703</u>	<u>45,693</u>

F Other information required by Listing Rule Appendix 7.2 (cont'd)

10 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) of the Listing Manual of the Singapore Exchange Securities Trading Limited as follows:

Name	Age	Family relationship with any Director and/or Substantial Shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Franky Oesman Widjaja	64	Brother of Muktar Widjaja, Director of GAR	<u>GAR:</u> Chairman and Chief Executive Officer since 2000 and 1996 respectively. Overall responsible for the strategic direction and management of the Group's operations.	No changes
Muktar Widjaja	67	Brother of Franky Oesman Widjaja, Director of GAR	<u>GAR:</u> Director and President since 1999 and 2000 respectively.	No changes
Jesslyne Widjaja	37	Daughter of Franky Oesman Widjaja, Niece of Muktar Widjaja, Directors of GAR	<u>GAR Group:</u> Director – Corporate Strategy & Business Development since 2014. Oversee all corporate strategy, business development and organizational development activities.	No changes

11 Confirmation pursuant to the Rule 720(1) of the listing manual

The Company confirms that it has procured undertakings from all its directors and executive officers in the form set out in Appendix 7.7 under Rule 720(1) of the Listing Manual.

BY ORDER OF THE BOARD

Rafael Buhay Concepcion, Jr.
Director
1 March 2022

Submitted by Kimberley Lye Chor Mei, Director, Corporate Secretarial on 1 March 2022 to the SGX